Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia.

  title={Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia.},
  author={Satomi S. Tanaka and Satoru Miyagi and Goro Sashida and Tetsuhiro Chiba and Jin Yuan and Makiko Mochizuki-Kashio and Yutaka Suzuki and Sumio Sugano and Chiaki Nakaseko and Koutaro Yokote and Haruhiko Koseki and Atsushi Iwama},
  volume={120 5},
EZH2, a catalytic component of the polycomb repressive complex 2, trimethylates histone H3 at lysine 27 (H3K27) to repress the transcription of target genes. Although EZH2 is overexpressed in various cancers, including some hematologic malignancies, the role of EZH2 in acute myeloid leukemia (AML) has yet to be examined in vivo. In the present study, we transformed granulocyte macrophage progenitors from Cre-ERT;Ezh2(flox/flox) mice with the MLL-AF9 leukemic fusion gene to analyze the function… CONTINUE READING
Highly Influential
This paper has highly influenced 10 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 78 extracted citations

New insights in AML biology from genomic analysis.

Seminars in hematology • 2014
View 3 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-10 of 45 references

Polycomb repressive complex 2 is required for MLL-AF9 leukemia.

Proceedings of the National Academy of Sciences of the United States of America • 2012

Similar Papers

Loading similar papers…